While cisplatin and carboplatin are active versus most common cancers, epithelial
malignancies are incurable when metastatic. Even if an initial response occurs, acquired …

Chemotherapy and molecularly targeted approaches represent two very different modes of
cancer treatment and each is associated with unique benefits and limitations. Both types of …

Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …

Purpose Early clinical studies with gefitinib showed promising efficacy and mild toxicity in
patients with advanced non–small-cell lung cancer (NSCLC). Thus, gefitinib was an ideal …

Purpose To determine whether the addition of pemetrexed to gefitinib (P+ G) provides
clinical benefit, compared with gefitinib monotherapy, in patients with advanced …

Purpose Erlotinib is clinically effective in patients with non–small-cell lung cancer (NSCLC)
who have adenocarcinoma, are never or limited former smokers, or have EGFR mutant …

The low rate of approval of novel anti-cancer agents underscores the need for better
preclinical models of therapeutic response as neither xenografts nor early-generation …

Purpose This study investigated whether sequential administration of erlotinib and
chemotherapy improves clinical outcomes versus chemotherapy alone in unselected …

Purpose Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor
receptor-2 and epidermal growth factor receptor kinase activity. The activity of vandetanib …

Purpose: This study was undertaken to select the optimal combination schedule of erlotinib
and pemetrexed for the treatment of relapsed non–small cell lung cancer (NSCLC) using a …